Lifestance Health [LFST] vs Chemed [CHE] Detailed Stock Comparison
Lifestance Health
NASDAQ
Loading...
Chemed
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Lifestance Health wins in 6 metrics, Chemed wins in 12 metrics, with 0 ties. Chemed appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Lifestance Health | Chemed | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -37.00 | 23.36 | Lifestance Health |
| Price-to-Book Ratio | 1.47 | 5.50 | Lifestance Health |
| Debt-to-Equity Ratio | 32.18 | 12.15 | Chemed |
| PEG Ratio | 0.44 | -1.00 | Chemed |
| EV/EBITDA | 41.49 | 14.94 | Chemed |
| Profit Margin (TTM) | -1.23% | 11.56% | Chemed |
| Operating Margin (TTM) | -0.85% | 11.00% | Chemed |
| EBITDA Margin (TTM) | N/A | 11.00% | N/A |
| Return on Equity | -1.11% | 24.14% | Chemed |
| Return on Assets (TTM) | 0.04% | 13.56% | Chemed |
| Free Cash Flow (TTM) | $85.69M | $367.97M | Chemed |
| Dividend Yield | N/A | 0.18% | N/A |
| 1-Year Return | -10.19% | -19.80% | Lifestance Health |
| Price-to-Sales Ratio (TTM) | 1.64 | 2.63 | Lifestance Health |
| Enterprise Value | $2.44B | $6.49B | Chemed |
| EV/Revenue Ratio | 1.86 | 2.58 | Lifestance Health |
| Gross Profit Margin (TTM) | 31.40% | 29.85% | Lifestance Health |
| Revenue per Share (TTM) | $3 | $170 | Chemed |
| Earnings per Share (Diluted) | $-0.04 | $19.44 | Chemed |
| Beta (Stock Volatility) | 1.13 | 0.46 | Chemed |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Lifestance Health vs Chemed Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Lifestance Health | 0.91% | 2.02% | 32.14% | -1.42% | -26.88% | -26.49% |
| Chemed | 1.09% | 3.13% | 1.36% | -18.24% | -16.11% | -13.05% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Lifestance Health | -10.19% | -15.14% | -76.88% | -76.88% | -76.88% | -76.88% |
| Chemed | -19.80% | -3.27% | -10.18% | 231.37% | 796.76% | 1,060.10% |
Performance & Financial Health Analysis: Lifestance Health vs Chemed
| Metric | LFST | CHE |
|---|---|---|
| Market Information | ||
| Market Cap | $2.16B | $6.62B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 3,662,190 | 148,040 |
| 90 Day Avg. Volume | 2,999,970 | 169,997 |
| Last Close | $5.55 | $459.05 |
| 52 Week Range | $3.74 - $8.61 | $408.42 - $623.61 |
| % from 52W High | -35.54% | -26.39% |
| All-Time High | $29.81 (Jul 05, 2021) | $654.62 (Mar 11, 2024) |
| % from All-Time High | -81.38% | -29.88% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.11% | 0.04% |
| Quarterly Earnings Growth | N/A | -0.26% |
| Financial Health | ||
| Profit Margin (TTM) | -0.01% | 0.12% |
| Operating Margin (TTM) | -0.01% | 0.11% |
| Return on Equity (TTM) | -0.01% | 0.24% |
| Debt to Equity (MRQ) | 32.18 | 12.15 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $3.79 | $82.56 |
| Cash per Share (MRQ) | $0.49 | $17.22 |
| Operating Cash Flow (TTM) | $146.34M | $426.78M |
| Levered Free Cash Flow (TTM) | $121.32M | $285.06M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.18% |
| Last 12-Month Dividend | N/A | $1.00 |
Valuation & Enterprise Metrics Analysis: Lifestance Health vs Chemed
| Metric | LFST | CHE |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -37.00 | 23.36 |
| Forward P/E | -32.65 | 18.24 |
| PEG Ratio | 0.44 | -1.00 |
| Price to Sales (TTM) | 1.64 | 2.63 |
| Price to Book (MRQ) | 1.47 | 5.50 |
| Market Capitalization | ||
| Market Capitalization | $2.16B | $6.62B |
| Enterprise Value | $2.44B | $6.49B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.86 | 2.58 |
| Enterprise to EBITDA | 41.49 | 14.94 |
| Risk & Other Metrics | ||
| Beta | 1.13 | 0.46 |
| Book Value per Share (MRQ) | $3.79 | $82.56 |
Financial Statements Comparison: Lifestance Health vs Chemed
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | LFST | CHE |
|---|---|---|
| Revenue/Sales | $332.97M | $646.94M |
| Cost of Goods Sold | $223.18M | $430.53M |
| Gross Profit | $109.79M | $216.41M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | $1.60M | $94.76M |
| EBITDA | $15.36M | $112.02M |
| Pre-Tax Income | $-1.47M | $95.67M |
| Income Tax | $-2.18M | $23.92M |
| Net Income (Profit) | $709,000 | $71.76M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | LFST | CHE |
|---|---|---|
| Cash & Equivalents | $134.34M | $173.88M |
| Total Current Assets | $304.63M | $502.39M |
| Total Current Liabilities | $207.39M | $290.56M |
| Long-Term Debt | $425.71M | $102.08M |
| Total Shareholders Equity | $1.46B | $1.18B |
| Retained Earnings | $-817.58M | $2.79B |
| Property, Plant & Equipment | $148.91M | $724.13M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | LFST | CHE |
|---|---|---|
| Operating Cash Flow | $23.35M | $34.75M |
| Capital Expenditures | $-7.17M | $112,000 |
| Free Cash Flow | $-10.26M | $19.46M |
| Debt Repayment | $-1.81M | N/A |
| Common Stock Repurchase | N/A | $-33.22M |
Short Interest & Institutional Ownership Analysis
| Metric | LFST | CHE |
|---|---|---|
| Shares Short | 7.41M | 384,385 |
| Short Ratio | 3.10 | 1.93 |
| Short % of Float | 0.09% | 0.03% |
| Average Daily Volume (10 Day) | 3,662,190 | 148,040 |
| Average Daily Volume (90 Day) | 2,999,970 | 169,997 |
| Shares Outstanding | 382.74M | 14.56M |
| Float Shares | 140.04M | 14.28M |
| % Held by Insiders | 0.08% | 0.02% |
| % Held by Institutions | 0.92% | 0.98% |
Dividend Analysis & Yield Comparison: Lifestance Health vs Chemed
| Metric | LFST | CHE |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.00 |
| Last 12-Month Dividend Yield | N/A | 0.18% |
| 3-Year Avg Annual Dividend | N/A | $1.37 |
| 3-Year Avg Dividend Yield | N/A | 0.08% |
| 3-Year Total Dividends | N/A | $4.10 |
| Ex-Dividend Date | N/A | Nov 18, 2024 |